Wall Street equity research analysts covering KORU Medical Systems have established a consensus 12-month average price target hovering between $6.60 and $7.33 per share, with higher estimates reaching up to $8.00. These forward-looking projections adjust dynamically based on quarterly revenue growth, regulatory updates, and commercial execution metrics across its subcutaneous infusion device portfolio on the Nasdaq exchange.